John Kiely Biography and Net Worth

Director of Amneal Pharmaceuticals

John Kiely has more than 35 years of financial leadership and advisory experience serving public companies, including multi-national corporations. Until June 2019 he served as Senior Assurance Partner at Pricewaterhouse Coopers, where he focused on the pharmaceutical, manufacturing chemical and medical device sectors. Since 1980, he has held various roles of increasing responsibility at Pricewaterhouse Coopers, including as U.S. Pharmaceutical Leader, Global Pharmaceutical Assurance Leader, Private Equity Assurance Leader and Assurance Chief Quality Officer. Mr. Kiely currently serves on the board at Zovio, Inc.

What is John Kiely's net worth?: The estimated net worth of John Kiely is at least $2.69 million as of August 27th, 2025. Mr. Kiely owns 225,433 shares of Amneal Pharmaceuticals stock worth more than $2,691,670 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Kiely may own. Learn More about John Kiely's net worth.
How do I contact John Kiely?: The corporate mailing address for Mr. Kiely and other Amneal Pharmaceuticals executives is 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807, United States. Amneal Pharmaceuticals can also be reached via phone at 908-947-3120 and via email at [email protected]. Learn More on John Kiely's contact information.
Has John Kiely been buying or selling shares of Amneal Pharmaceuticals?: John Kiely has not been actively trading shares of Amneal Pharmaceuticals during the last quarter. Most recently, John Kiely sold 32,000 shares of the business's stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $9.23, for a transaction totalling $295,360.00. Following the completion of the sale, the director now directly owns 225,433 shares of the company's stock, valued at $2,080,746.59. Learn More on John Kiely's trading history.
Who are Amneal Pharmaceuticals' active insiders?: Amneal Pharmaceuticals' insider roster includes Andrew Boyer (EVP, Chief Commercial Officer – Generics), Jason Daly (SVP), John Kiely (Director), Ted Nark (Director), Chirag Patel (Co-Founder, Co-CEO, President & Director), Gautam Patel (Director), Nikita Shah (EVP), and Joseph Todisco (EVP). Learn More on Amneal Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amneal Pharmaceuticals?: During the last year, insiders at the sold shares 16 times. They sold a total of 6,081,062 shares worth more than $52,198,348.02. The most recent insider tranaction occured on November, 17th when Director Ted C Nark sold 50,000 shares worth more than $586,000.00. Insiders at Amneal Pharmaceuticals own 26.6% of the company. Learn More about insider trades at Amneal Pharmaceuticals.
Information on this page was last updated on 11/17/2025.

John Kiely Insider Trading History at Amneal Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/27/2025	Sell	32,000	$9.23	$295,360.00	225,433
5/19/2020	Buy	10,000	$4.53	$45,300.00

John Kiely Buying and Selling Activity at Amneal Pharmaceuticals

Amneal Pharmaceuticals Company Overview

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Today's Range

Now: $11.94

$11.71

$12.22

50 Day Range

MA: $10.99

$9.72

$12.59

2 Week Range

Now: $11.94

$6.68

$12.68

Volume

2,054,676 shs

Average Volume

1,712,975 shs

Market Capitalization

$3.75 billion

P/E Ratio

597.30

Dividend Yield

N/A

Beta

1.36